The Division of Oncology 2 (DO2) regulates Investigational New Drug Applications (INDs), New Drug Applications (NDAs) and Biologic Licensing Applications (BLAs) for the following therapeutic areas: gastrointestinal, lung, and head and neck cancers; neuro-oncology, rare cancers, pediatric
Similar Posts
Esophageal pH Monitoring Capsule Recall: Medtronic and Given Imaging Remove Bravo CF Capsule Delivery Devices
This communication is part of the Communications Pilot to Enhance the Medical Device Recall ProgramCounterfeit Medicine
Counterfeit (fake or falsified) medicines may be harmful to your health because while being passed off as authentic, may contain the wrong ingredients, contain too much, too little or no active ingredient at all or contain other harmful ingredients.Pacific International Marketing Recalls Fresh Italian Parsley Because of Possible Health Risk
Salinas, CA (October 28, 2025) – Pacific International Marketing (“Pacific”) is recalling 474 cases of bulk Italian Parsley because it may be contaminated with Salmonella, an organism that can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weSandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Cefazolin for Injection Due to Product Mispackaging
Sandoz, Inc. (“Sandoz”) is initiating a voluntary recall of one (1) lot of Cefazolin for Injection, USP, 1 gram per vial.Broselow Pediatric Emergency Rainbow Tape Recall: AirLife Removes Certain Broselow Pediatric Emergency Rainbow Tapes due to Misprinted Information
Certain Broselow Pediatric Emergency Rainbow Tapes were manufactured with incorrect information on the tape.Generic Drugs Forum (GDF) 2026 – 04/22/2026
FDA’s annual Generic Drugs Forum is a two-day event designed to facilitate the development and approval of safe, effective, and high-quality generic medicines. Join us April 22-23, 2026.